1. Home
  2. BIIB vs TSN Comparison

BIIB vs TSN Comparison

Compare BIIB & TSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • TSN
  • Stock Information
  • Founded
  • BIIB 1978
  • TSN 1935
  • Country
  • BIIB United States
  • TSN United States
  • Employees
  • BIIB N/A
  • TSN N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • TSN Meat/Poultry/Fish
  • Sector
  • BIIB Health Care
  • TSN Consumer Staples
  • Exchange
  • BIIB Nasdaq
  • TSN Nasdaq
  • Market Cap
  • BIIB 18.8B
  • TSN 19.8B
  • IPO Year
  • BIIB 1991
  • TSN N/A
  • Fundamental
  • Price
  • BIIB $125.00
  • TSN $55.92
  • Analyst Decision
  • BIIB Buy
  • TSN Hold
  • Analyst Count
  • BIIB 27
  • TSN 9
  • Target Price
  • BIIB $188.17
  • TSN $63.11
  • AVG Volume (30 Days)
  • BIIB 1.3M
  • TSN 2.5M
  • Earning Date
  • BIIB 07-31-2025
  • TSN 08-04-2025
  • Dividend Yield
  • BIIB N/A
  • TSN 3.57%
  • EPS Growth
  • BIIB 26.39
  • TSN N/A
  • EPS
  • BIIB 10.12
  • TSN 2.57
  • Revenue
  • BIIB $9,816,400,000.00
  • TSN $53,615,000,000.00
  • Revenue This Year
  • BIIB N/A
  • TSN $2.42
  • Revenue Next Year
  • BIIB N/A
  • TSN $2.01
  • P/E Ratio
  • BIIB $12.41
  • TSN $21.81
  • Revenue Growth
  • BIIB 1.59
  • TSN 1.39
  • 52 Week Low
  • BIIB $110.04
  • TSN $54.01
  • 52 Week High
  • BIIB $238.00
  • TSN $66.88
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 45.14
  • TSN 52.77
  • Support Level
  • BIIB $123.21
  • TSN $54.64
  • Resistance Level
  • BIIB $129.27
  • TSN $55.90
  • Average True Range (ATR)
  • BIIB 3.00
  • TSN 0.77
  • MACD
  • BIIB -0.77
  • TSN 0.18
  • Stochastic Oscillator
  • BIIB 21.06
  • TSN 90.71

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About TSN Tyson Foods Inc.

Tyson Foods is a protein-focused food producer, selling raw chicken, beef, pork, and prepared foods. Chicken and beef are its two largest segments, each composing about one third of US sales. Prepared foods constituted 18% of fiscal 2024 sales and include brands like Tyson, Jimmy Dean, Hillshire Farm, Ball Park, and Sara Lee. However, most of these are in product categories rife with competition where Tyson does not have a massive market share lead. Tyson sells some products overseas, but the international segment accounts for just 4% of total revenue. The company is an active acquirer, with more recent years' purchases focused on international and food-service markets.

Share on Social Networks: